Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials

Item
http://www.wikidata.org/entity/Q26825636
Nintedanib in NSCLC: evidence to date and place in therapyDacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?Extraordinary and prolonged erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report.Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer.Assessment and prognostic analysis of EGFR mutations or/and HER2 overexpression in Uygur's Non-small Cell Lung Cancer.The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR statusPemetrexed-carboplatin with intercalated icotinib in the treatment of patient with advanced EGFR wild-type lung adenocarcinoma: A case reportEfficacy of second-line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non-small cell lung cancer without epidermal growth factor receptor mutations.Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study.Involvement of GLUT1-mediated glucose transport and metabolism in gefitinib resistance of non-small-cell lung cancer cells
P2860

Should Tyrosine Kinase Inhibitors Be Considered for Advanced Non-Small-Cell Lung Cancer Patients With Wild Type EGFR? Two Systematic Reviews and Meta-Analyses of Randomized Trials

Item
http://www.wikidata.org/entity/Q26825636
description
2015 nî lūn-bûn
@nan
2015 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@ast
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@en
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@nl
type
label
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@ast
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@en
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@nl
prefLabel
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@ast
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@en
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@nl
P1433
P1476
P2093
P275
P2860
P304
P31
P356
P407
P433
P478
P50
P5008
P577
P5875
P698
P921
P932
P356
P1433
P1476
Should Tyrosine Kinase Inhibit ...... -Analyses of Randomized Trials
@en
P2093
P275
P2860
P304
P31
P356
10.1016/J.CLLC.2014.11.007
P407
P433
P478
P50
P5008
P577
P5875
P698
P921
P932